

Special Issue

Phage and Antibiotic Combination Therapy against MDR Bacteria

Message from the Guest Editor

It is anticipated that phage therapy combined with antibiotics will have considerable synergistic therapeutic effects. However, antagonistic effects have also been reported. As phages are unprecedented and variable in many respects, there may also be wide variations between them with regards to interactions between different antibiotics. There is high interest to collect experiences on the topic, both in vitro and in vivo. Therefore, we propose the launch of a new Special Issue, titled “Phage and Antibiotic Combination Therapy against MDR Bacteria”, with myself acting as a . We welcome original articles, reviews, short communications, and case reports on the topic.

Guest Editor

Dr. Mikael Skurnik

Department of Bacteriology and Immunology, Medicum, University of Helsinki, Helsinki, Finland

Deadline for manuscript submissions

closed (30 November 2022)



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/114341

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,
National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).